These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17222198)

  • 41. The benefit of induction chemotherapy in patients age > or = 75 years.
    Vey N; Coso D; Bardou VJ; Stoppa AM; Braud AC; Bouabdallah R; Sainty D; Mozziconacci MJ; Lafage M; Damaj G; Blaise D; Gastaut JA; Maraninchi D
    Cancer; 2004 Jul; 101(2):325-31. PubMed ID: 15241830
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
    Anderlini P; Luna M; Kantarjian HM; O'Brien S; Pierce S; Keating MJ; Estey EH
    Leukemia; 1996 Apr; 10(4):600-8. PubMed ID: 8618434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.
    Damiani D; Tiribelli M; Michelutti A; Geromin A; Cavallin M; Fabbro D; Pianta A; Malagola M; Damante G; Russo D; Fanin R
    Leuk Res; 2010 Jul; 34(7):942-5. PubMed ID: 20122734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody binding capacity for evaluation of MDR-related proteins in acute promyelocytic leukemia: Onset versus relapse expression.
    Damiani D; Michieli M; Michelutti A; Candoni A; Stocchi R; Masolini P; Geromin A; Michelutti T; Raspadori D; Ippoliti M; Lauria F; Fanin R
    Cytometry B Clin Cytom; 2004 May; 59(1):40-5. PubMed ID: 15108169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia.
    Trnková Z; Bedrlíková R; Marková J; Michalová K; Stöckbauer P; Schwarz J
    Neoplasma; 2007; 54(5):383-90. PubMed ID: 17688368
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome.
    Schaich M; Harbich-Brutscher E; Pascheberg U; Mohr B; Soucek S; Ehninger G; Illmer T
    Haematologica; 2002 May; 87(5):455-64. PubMed ID: 12010657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells.
    Suárez L; Vidriales MB; Moreno MJ; López A; García-Laraña J; Pérez-López C; Tormo M; Lavilla E; López-Berges MC; de Santiago M; San Miguel JF; Orfao A;
    Haematologica; 2005 Jan; 90(1):54-9. PubMed ID: 15642669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group.
    Koistinen P; Räty R; Itälä M; Jantunen E; Koivunen E; Nousiainen T; Pelliniemi TT; Remes K; Ruutu T; Savolainen ER; Siitonen T; Silvennoinen R; Volin L; Elonen E;
    Eur J Haematol; 2007 Jun; 78(6):477-86. PubMed ID: 17391337
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
    Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
    J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.
    Lo-Coco F; Cuneo A; Pane F; Cilloni D; Diverio D; Mancini M; Testoni N; Bardi A; Izzo B; Bolli N; La Starza R; Fazi P; Iacobelli S; Piciocchi A; Vignetti M; Amadori S; Mandelli F; Pelicci PG; Mecucci C; Falini B; Saglio G;
    Haematologica; 2008 Jul; 93(7):1017-24. PubMed ID: 18508799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
    Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
    Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience.
    Pulsoni A; Iacobelli S; Bernardi M; Borgia M; Camera A; Cantore N; Di Raimondo F; Fazi P; Ferrara F; Leoni F; Liso V; Mancini M; Marmont F; Matturro A; Maurillo L; Melillo L; Meloni G; Mirto S; Specchia G; Valentini CG; Venditti A; Leone G; Foà R; Mandelli F; Pagano L
    Haematologica; 2008 Jul; 93(7):1025-32. PubMed ID: 18508801
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia.
    Roberson JR; Onciu M; Pounds S; Rubnitz JE; Pui CH; Razzouk BI
    Pediatr Blood Cancer; 2008 Mar; 50(3):542-8. PubMed ID: 17763467
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phenotypic quantitative features of patients with acute myeloid leukemia.
    Pereira FG; Metze K; Costa FP; Lima CS; Lorand-Metze I
    Neoplasma; 2006; 53(2):155-60. PubMed ID: 16575472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
    Latagliata R; Breccia M; Fazi P; Iacobelli S; Martinelli G; Di Raimondo F; Sborgia M; Fabbiano F; Pirrotta MT; Zaccaria A; Amadori S; Caramatti C; Falzetti F; Candoni A; Mattei D; Morselli M; Alimena G; Vignetti M; Baccarani M; Mandelli F
    Br J Haematol; 2008 Dec; 143(5):681-9. PubMed ID: 18950458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies.
    de Greef GE; van Putten WL; Boogaerts M; Huijgens PC; Verdonck LF; Vellenga E; Theobald M; Jacky E; Löwenberg B; ;
    Br J Haematol; 2005 Jan; 128(2):184-91. PubMed ID: 15638852
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia.
    Thomas X; Campos L; Mounier C; Cornillon J; Flandrin P; Le QH; Piselli S; Guyotat D
    Leuk Res; 2005 Sep; 29(9):1049-58. PubMed ID: 16038731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.